Instil Bio
Sandeep "Steve" Laumas has a diverse and extensive work experience spanning over two decades. Sandeep "Steve" currently holds the position of Chief Business Officer and Chief Financial Officer at Instil Bio since 2020. Previously, they served as a Managing Director at Bearing Circle Capital from 2008.
In the biotechnology sector, Laumas has played key roles as a member of the Board of Directors and Chair of the Audit Committee at BioXcel Therapeutics, Inc. and as a member of the Board of Directors at 9 Meters Biopharma, Inc.
Earlier in their career, Laumas held management positions at North Sound Capital from 2003 to 2007 and worked as an Analyst at Balyasny Asset Management L.P. from 2001 to 2002. Sandeep "Steve" began their professional journey as an Associate at Goldman Sachs from 1996 to 2000.
Overall, Laumas brings a wealth of experience and expertise to their current and previous roles in the finance and biotechnology industries.
Sandeep "Steve" Laumas started their education in 1986 at Cornell University, where they pursued a Bachelor of Arts (A.B.) degree in Chemistry. After completing their undergraduate studies in 1990, they enrolled at Albany Medical College, where they spent five years studying medicine and earned a Doctor of Medicine (M.D.) degree. During their time at Albany Medical College, they also conducted research at the Dana-Farber Cancer Institute from 1992 to 1993. Following their medical studies, they pursued further training and completed an Internship in Medicine at Yale University School of Medicine from 1995 to 1996.
This person is not in any offices
Instil Bio
1 followers
Instil Bio is a cell therapy company developing tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers. TIL are a patient’s own T cells harvested from the patient’s tumor, which are then expanded and reinfused into the patient to target and kill cancer cells. The company is advancing its proprietary manufacturing expertise, technology, and data into clinical trials, including a planned registrational study with its lead candidate and a first-in-human study of its next-generation engineered TIL. The company is led by world-class cell therapy experts and backed by premier global institutional investors. Instil is located in the greater Los Angeles area with additional manufacturing and research facilities in Manchester, UK.